Prothena Corporation plc Ordinary Shares
PRTAProthena Corporation plc is a biotechnology company focused on developing therapies for neurodegenerative and rare diseases. Founded in 2012 and headquartered in Dublin, Ireland, it leverages its expertise in immunology and protein biology to create innovative treatments, primarily targeting conditions such as Alzheimer's disease, Parkinson's disease, and other amyloid-related disorders. The company's approach often involves antibody discovery, molecular engineering, and collaboration with partners to advance its drug pipeline.
Company News
Novo Nordisk presented Phase 2 trial results for Coramitug, an antibody targeting transthyretin amyloidosis with cardiomyopathy (ATTR-CM). The drug showed a statistically significant reduction in heart failure biomarker NT-proBNP and was well-tolerated.
Kuehn Law, a shareholder litigation law firm, is investigating potential self-dealing by officers and directors of Prothena Corporation PLC. Shareholders may be entitled to damages and corporate governance reforms.
Prothena (PRTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Biogen stock is rising as investors double down on the company’s promising yet still experimental treatment for Alzheimer’s disease.
Positive results for Biogen's Alzheimer's disease candidate are boosting all three stocks.
